Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […] Read More